- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07903688
Meditation and Yogic Breathing-driven Modulation of Neurofluid Coupling and Brain Clearance (SPANDHA)
This study will examine whether meditation and yogic breathing can alter brain fluid movement and waste clearance in healthy adults. It will also evaluate the GLYMPHOMETER, a new external forehead-worn device designed to objectively measure changes in brain fluid movement and exchange during meditation.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The glymphatic system is a brain waste-clearance pathway that facilitates the movement of cerebrospinal fluid (CSF) and interstitial fluid and is thought to play an important role in maintaining brain homeostasis. Emerging evidence suggests that respiration, autonomic activity, and changes in cerebral blood flow may influence CSF dynamics and related neurofluid processes. However, the effects of voluntary breathing practices and meditation on these physiological mechanisms in humans remain incompletely understood.
The SPANDHA study will investigate whether structured yogic breathing (Pranayama; specifically Nadi Shuddhi) and/or meditation (Shoonya meditation) are associated with changes in neurofluid dynamics and related physiological measures. The study will use the GLYMPHOMETER, a forehead-mounted multimodal device designed to measure physiological signals associated with neurofluid coupling during naturalistic meditation and breathing practices. The system incorporates multi-wavelength electroencephalography (EEG) and near-infrared spectroscopy (NIRS) to characterize changes in cerebral electrical activity, cerebral hemodynamics, and neurofluid-related dynamics while participants engage in the interventions.
The study will enroll approximately 100 participants, including 50 novice and 50 experienced practitioners. Using a 2-sequence crossover, participants will complete two study visits involving meditation and yogic breathing conditions. The study will evaluate changes in measures of neurofluid dynamics, cerebral compliance, autonomic regulation including heart-rate variability (HRV), and EEG-derived brain states associated with the interventions. Participants will be stratified by experience level (novice/advance) and randomized within each stratum to one of the two intervention sequences.
A subset of participants will undergo additional validation assessments using phase-contrast magnetic resonance imaging (MRI) and blood-based biomarkers. These assessments will be used to examine the relationship between measurements obtained with the GLYMPHOMETER and established measures of CSF and cerebrovascular physiology.
The primary objective of the study is to characterize the acute physiological effects of meditation and yogic breathing on neurofluid dynamics and related brain and autonomic measures. The findings may provide preliminary evidence regarding the feasibility of using voluntary breathing and meditation practices to modulate physiological processes associated with glymphatic function and may inform future studies of non-pharmacological approaches to brain health.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Balachundhar Subramaniam, MD MPH
- Numéro de téléphone: (781) 472-0572
- E-mail: bsubrama@bidmc.harvard.edu
Lieux d'étude
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- BIDMC
-
Contact:
- Deepthi R Johal, PhD
- Numéro de téléphone: 8574263244
- E-mail: drajashe@bidmc.harvard.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Healthy adults, 25-60 years old.
- Novice or Advanced as defined above.
- Fluent in English.
- Able to travel to BIDMC site for two days approximately 3-7 days apart.
Exclusion Criteria:
- History of neurological and/or neurodegenerative disorders (e.g., epilepsy, stroke, mild cognitive impairment, dementia)
- History of cardiovascular and respiratory illnesses
- History of major psychiatric disorders (e.g., schizophrenia, bipolar disorder)
- Currently diagnosed mental health issues (e.g., anxiety, depression)
- Current use of psychoactive medications, including medications prescribed for anxiety, depression, or other psychiatric conditions, or current use of stimulants or other medications that may substantially affect central nervous system function or study outcomes.
- Skin ailments, abrasions or contusions, particularly located on the forehead and face
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Non randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Novice Meditators
Less than 1 year of consistent meditation practice. |
Nadi Shuddhi is a structured yogic breathing practice involving slow, alternating respiration through the left and right nostrils in a prescribed sequence. Shoonya meditation is a structured contemplative practice characterized by conscious non-doing, in which participants maintain a relaxed, alert state while minimizing deliberate attentional selection, cognitive elaboration, and engagement with internal or external stimuli. |
|
Comparateur actif: Advanced Meditators
More than 5 years or a minimum of 2500 hours of consistent meditation practice |
Nadi Shuddhi is a structured yogic breathing practice involving slow, alternating respiration through the left and right nostrils in a prescribed sequence. Shoonya meditation is a structured contemplative practice characterized by conscious non-doing, in which participants maintain a relaxed, alert state while minimizing deliberate attentional selection, cognitive elaboration, and engagement with internal or external stimuli. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Acquisition of physiological data using the GLYMPHOMETER during meditation and yogic breathing sessions.
Délai: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
|
Participants meeting threshold for analyzable device recordings. |
At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Neurofluid-related physiological measures during Shoonya meditation and Nadi Shuddhi breathing.
Délai: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
|
Changes in GLYMPHOMETER-derived measures of neurofluid coupling, during Shoonya meditation and Nadi Shuddhi breathing. (Measurement device: Glymphometer; Measure: Neurofluid coupling aka Fluid dynamics in brain) |
At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
|
|
Autonomic regulation during Shoonya meditation and Nadi Shuddhi breathing.
Délai: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
|
Changes in heart-rate variability (HRV) during Shoonya meditation and Nadi Shuddhi breathing. |
At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
|
|
Very-low-frequency physiological signal characteristics
Délai: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
|
Changes in predefined very-low-frequency (0.001-0.1 Hz) signal characteristics derived from GLYMPHOMETER medical™ recordings and their relationship to neurofluid-related measures. |
At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Differences in neurophysiological responses according to meditation experience.
Délai: From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
|
Comparison of changes in GLYMPHOMETER-derived measures of neurofluid coupling between novice and advanced meditators. |
From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
|
|
Mindful Attention Awareness Scale
Délai: Once at Baseline. Estimated acquisition window: 5-8 minutes
|
We assess for change in Mindfulness levels by using a validated scale for this purpose namely, Mindfulness Attention Awareness Scale (MAAS). The scale measures the individuals' ability for receptive awareness and attention to present. This aids in evaluating any change on the individual's awareness levels after the Inner engineering intervention. We compute the MAAS scores for each participant which is a mean score for 15 item questionnaires and compare the pre & post intervention results to look for change. Participants are asked to rate on a scale of 1 (Almost Always) to 6 (Almost Never) to assess the frequency of occurrence of each experience. Mean is then computed using items from each of the 15 questions to create a MAAS score, ranging from 0 to 6. Higher MAAS scores indicate better mindfulness state. |
Once at Baseline. Estimated acquisition window: 5-8 minutes
|
|
Meditation Depth Questionnaires
Délai: At each study visit after the meditation practice is completed. Expected acquisition window: 10-15 minutes; Total number of visits: 2
|
This 30-item measure assesses the subjective depth of meditation across progressively deeper experiential states. Items are typically rated on a 5-point Likert scale and are grouped into five empirically derived domains: hindrances, relaxation, personal-self/concentration, essential/transpersonal qualities, and transpersonal-self/non-duality. Together, these domains capture experiences ranging from obstacles and relaxation during meditation to focused concentration, transpersonal qualities, and experiences of diminished self-boundaries or non-dual awareness. |
At each study visit after the meditation practice is completed. Expected acquisition window: 10-15 minutes; Total number of visits: 2
|
|
Correlation between GLYMPHOMETER-derived neurofluid metrics and MRI-based neurofluid dynamics (Validation of Portable Device).
Délai: From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
|
This outcome evaluates the concurrent validity of the portable device against the gold standard. The statistical method will be a correlation analysis (Pearson or Spearman, as appropriate based on data distribution).
|
From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
|
|
Correlation between GLYMPHOMETER-derived neurofluid metrics and plasma brain-derived biomarkers.
Délai: From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
|
This outcome evaluates the relationship between neurofluid dynamics and blood-based markers of brain clearance. The statistical method will be a correlation analysis (Pearson or Spearman).
|
From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
|
|
Qualitative assessment of meditation and breathing experiences.
Délai: At each study visit after the meditation practice is completed. Expected acquisition window: 30 minutes; Total number of visits: 2
|
Qualitative characterization of participant experiences using one-on-one micro-phenomenological interviews. |
At each study visit after the meditation practice is completed. Expected acquisition window: 30 minutes; Total number of visits: 2
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- 2026P000655
- GRT69415 (Autre subvention/numéro de financement: Inner Science Research Foundation)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .